Biocodex promotes Berry to director of marketing
SAN BRUNO, Calif. Biocodex on Friday promoted Mary Berry to the position of director of marketing, reporting to Marc Rohman, VP and managing director of U.S. operations Biocodex.
“[Berry] has successfully increased brand awareness of Florastor in the U.S., and through her creative efforts has successfully contributed to increased sales of our flagship product,” Rohman said.
In her new role, Berry will continue to lead Biocodex’ marketing of Florastor as well as assist in the company’s mission to seek out and secure new products.
FDA targets marketer that claims its products treat swine flu
ROCKVILLE, Md. The Food and Drug Administration on Monday targeted ReBuilder Medical Technologies as a renegade marketer pitching its $199 “SilverCure Swine Flu Protection Pack,” that includes shampoo, lotion, conditioner and soap that supposedly deposit traces of silver according to published reports, as a product indicated for the prevention or treatment of the new H1N1 influenza virus known as the “swine flu.”
“Once included, all websites and products will remain listed,” the FDA stated. “After FDA has verified that the products or the objectionable claims related to the 2009 H1N1 Flu Virus have been removed from the web site, this information will be added to the list.”
ReBuilder Medical is attempting to capitalize on its increased web traffic with a message for browsers: “Note: Sorry, ReBuilder Medical does not sell flu products. Reporter’s mistake. Not one of the “20 sites”, but as long as you are here, please read.” In its place, ReBuilder is pitching its ReBuilder Electronic Neuromuscular Stimulator, a device that delivers small electrical shocks for pain relief.
However, a Google search for “SilverCure swine flu,” generates the URL http://www.rebuildermedical.com/outbreak/, which at one time contained the following copy: “One oz. jar of SilverCure to swab into your nose with a fresh Q-tip to coat … Because the Swine flu virus is airborne, it may settle on your hair and then ….”
That site now features the message: “This market test has voluntarily ended.”
Herbal Groups advertising referred to FDA for review
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday referred advertising published by Herbal Groups to the Federal Trade Commission and the Food and Drug Administration (FDA) for further review.
NAD, the advertising industry’s self-regulatory forum, had asked Herbal Groups to provide substantiation for health claims made for Prostalex Plus, which included: “Prostalex Plus has been shown in clinical studies to reduce the size of the prostate, leading to a reduced urge to urinate, improvement in urinary flow, improvement in erectile issues and increased sex drive.”
Further, NAD was concerned that “the Prostate Health Blog,” which is linked to the advertiser’s Web site and appears to be an independently written blog, is actually advertising by the company.
In response to the NAD inquiry, the advertiser submitted a study on Prostalex, but declined to participate in the NAD process. Pursuant to Section 2.9 of the NAD/NARB Procedures, NAD referred this matter to the FTC and FDA for review.